Navigation Links
Legislative and Regulatory Outlook - 2009 and Beyond for Pharma, Biotech Players
Date:2/13/2008

NEW YORK, Feb. 13 /PRNewswire/ -- Today, more than ever before, pharmaceutical sales and marketing executives are facing challenges from all sides. Internally, the pressure to fill pipelines, demands for more R&D results, and competition from generics demand new outcomes from pharmaceutical marketing and sales teams across the board.

Externally, new U.S.-based regulatory (e.g. post-approval monitoring), legislative, and patent issues continue to loom. Changes affecting the sales and marketing functions of the industry are inevitable as a new administration takes control of the FDA, FTC and other agencies in 2009.

International Institute for Business Information & Growth (iiBIG) presents the 2nd Annual Pharmaceutical Sales & Marketing Executive Congress, scheduled for March 31 - April 1, 2008 in Bethesda, Maryland. This year's conference will outline trends, case studies, and best-practices required to reformulate pharmaceutical marketing and sales strategies in the light of the new rules of engagement. Two new speakers to join our speaking faculty are:

-- Adriane Fugh-Berman MD, Associate Professor, Complementary and

Alternative Medicine Masters Program, Department of Physiology and

Biophysics, Georgetown University

Dr. Fugh-Berman will discuss important developments from the physician side and how physicians are responding to some irregular and wrong practices in pharma CME.

-- Lori Ryan, Executive Director, Head of Finance CVM Sales Force,

Novartis Pharmaceuticals

Ms. Ryan joins our panel on the State of the Industry - Challenges & Opportunities in 2008 and Beyond, joining distinguished faculty from Best Practices, Jazz Pharmaceuticals, and Scientific Advantage.

Dr. Fugh-Berman and Ms. Ryan joins top industry leaders in this field including Hon. Gene Green (D-TX), Member, Health Subcommittee - Energy & Commerce Committee, U. S. House of Representatives; Paul J. Savidge, VP, Global Labeling & Compliance, Bristol-Myers Squibb; Liliana A. Gil, Worldwide Director of Marketing Services & Hispanic Strategy Lead, Johnson & Johnson; and Ellen Shapiro, Director, Division of Communications, Center for Drug Evaluation and Research (CDER), FDA.

This year's agenda will review the latest developments - legislative and otherwise - from Capitol Hill to burgeoning competition to missed opportunities affecting Big Pharma's marketing, sales, and compliance efforts for market dominance.

For Conference Updates and Speaker Roster: http://www.iibig.com/P0802.


'/>"/>
SOURCE iiBIG
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Healing Our Land, Inc. and The Massachusetts Black Legislative Caucus Convene Prevention Is Power Community Forum on the Impact of HIV/AIDS on Communities of Color in Massachusetts
2. MichBio Announces Formation of Biotechnology Legislative Caucus
3. Hospital-led Coalition Cautions Motorists on New Risks October 1, Lauds Legislative Leaders for Scheduling No-fault Hearings Next Week
4. University of Texas Study Details Lengthy Payment Delays for Medicare Part D Prescription Drug Claims, Confirming Need for Legislative Fix
5. AHCA: Rescinding $2.7 Billion Medicare Cuts Top Issue for Fall Legislative Agenda
6. Cipher provides CIP-TRAMADOL ER regulatory update
7. Mybank Goes Live With Misys Equation to Support Rapid Growth and Meet Future Regulatory Requirements
8. Mannatech Names New VP of Regulatory Affairs, Quality Assurance
9. Cardiome And Astellas Announce Regulatory Update
10. CuraGen and TopoTarget Report Belinostat Results Presented at ASH and Provide Regulatory Update Following End-of-Phase II Meeting with FDA
11. Medarex to Receive Milestone Payment for Submission of Regulatory Applications Requesting Approval of Ustekinumab (CNTO 1275) for Treatment of Psoriasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... 2016 , ... Austin residents seeking Mohs surgery services, can now turn to ... Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to ... fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding emergency ... its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. Ogunleye ... M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. Ogunleye ...
(Date:6/25/2016)... , ... June 25, 2016 , ... On Friday, June ... a Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments ... of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott ...
(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... Those ... deal with these feelings, many turn to unhealthy avenues, such as drug or alcohol ... of Marne, Michigan, has released tools for healthy coping following a traumatic event. , ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... OAKLAND, N.J. , June 24, 2016 /PRNewswire/ ... in the design, development and manufacturing of collagen ... and regeneration announced today that Bill Messer ... Sales and Marketing to further leverage the growing ... surgery medical devices. Bill joins the ...
(Date:6/24/2016)... , June 24, 2016 The Academy ... of recommendations that would allow biopharmaceutical companies ... with entities that make formulary and coverage decisions, a ... "value" of new medicines. The recommendations address ... not appear on the drug label, a prohibition that ...
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ... company developing innovative inhaled drugs, announced today that it ... Russell Investments reconstituted its comprehensive set of U.S. ... "This is an important milestone for Pulmatrix," said ... increase shareholder awareness of our progress in developing drugs ...
Breaking Medicine Technology: